Design, synthesis and biological evaluation of novel MDH inhibitors targeting tumor microenvironment

Cited 7 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorS Godesi-
dc.contributor.authorJeong-Ran Han-
dc.contributor.authorJang Keun Kim-
dc.contributor.authorD I Kwak-
dc.contributor.authorJ Lee-
dc.contributor.authorH Nada-
dc.contributor.authorM Kim-
dc.contributor.authorHyun A Yang-
dc.contributor.authorJoo-Young Im-
dc.contributor.authorHyun Seung Ban-
dc.contributor.authorC H Lee-
dc.contributor.authorY Choi-
dc.contributor.authorMi Sun Won-
dc.contributor.authorK Lee-
dc.date.accessioned2023-06-02T16:33:41Z-
dc.date.available2023-06-02T16:33:41Z-
dc.date.issued2023-
dc.identifier.issn1424-8247-
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/32032-
dc.description.abstractMDH1 and MDH2 enzymes play an important role in the survival of lung cancer. In this study, a novel series of dual MDH1/2 inhibitors for lung cancer was rationally designed and synthesized, and their SAR was carefully investigated. Among the tested compounds, compound 50 containing a piperidine ring displayed an improved growth inhibition of A549 and H460 lung cancer cell lines compared with LW1497. Compound 50 reduced the total ATP content in A549 cells in a dose-dependent manner; it also significantly suppressed the accumulation of hypoxia-inducible factor 1-alpha (HIF-1α) and the expression of HIF-1α target genes such as GLUT1 and pyruvate dehydrogenase kinase 1 (PDK1) in a dose-dependent manner. Furthermore, compound 50 inhibited HIF-1α-regulated CD73 expression under hypoxia in A549 lung cancer cells. Collectively, these results indicate that compound 50 may pave the way for the development of next-generation dual MDH1/2 inhibitors to target lung cancer.-
dc.publisherMDPI-
dc.titleDesign, synthesis and biological evaluation of novel MDH inhibitors targeting tumor microenvironment-
dc.title.alternativeDesign, synthesis and biological evaluation of novel MDH inhibitors targeting tumor microenvironment-
dc.typeArticle-
dc.citation.titlePharmaceuticals-
dc.citation.number5-
dc.citation.endPage683-
dc.citation.startPage683-
dc.citation.volume16-
dc.contributor.affiliatedAuthorJeong-Ran Han-
dc.contributor.affiliatedAuthorJang Keun Kim-
dc.contributor.affiliatedAuthorHyun A Yang-
dc.contributor.affiliatedAuthorJoo-Young Im-
dc.contributor.affiliatedAuthorHyun Seung Ban-
dc.contributor.affiliatedAuthorMi Sun Won-
dc.contributor.alternativeNameGodesi-
dc.contributor.alternativeName한정란-
dc.contributor.alternativeName김장근-
dc.contributor.alternativeName곽동익-
dc.contributor.alternativeName이주한-
dc.contributor.alternativeNameNada-
dc.contributor.alternativeName김민경-
dc.contributor.alternativeName양현아-
dc.contributor.alternativeName임주영-
dc.contributor.alternativeName반현승-
dc.contributor.alternativeName이창훈-
dc.contributor.alternativeName최용석-
dc.contributor.alternativeName원미선-
dc.contributor.alternativeName이경-
dc.identifier.bibliographicCitationPharmaceuticals, vol. 16, no. 5, pp. 683-683-
dc.identifier.doi10.3390/ph16050683-
dc.subject.keywordMDH1/2-
dc.subject.keywordInhibitors-
dc.subject.keywordHIF-1α-
dc.subject.keywordLung cancer-
dc.subject.localInhibitor-
dc.subject.localInhibitors-
dc.subject.localinhibitor-
dc.subject.localinhibitors-
dc.subject.localHIF-1α-
dc.subject.localHIF1α-
dc.subject.localHif1α-
dc.subject.locallung cancer-
dc.subject.localLung cancer-
dc.subject.localLung Cancer-
dc.description.journalClassY-
Appears in Collections:
Division of A.I. & Biomedical Research > Genomic Medicine Research Center > 1. Journal Articles
Division of A.I. & Biomedical Research > Biotherapeutics Translational Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.